Archives     Advertise     Editorial Calendar      Advertiser Index     Subscribe     Contact Us    


Bold Goals in Breast Cancer


 
Paula Schneider

Addressing Disparities, Deploying Research in a Race to Cure

What started as a promise to a dying sister has turned into an international force to fight breast cancer. Today, Susan G. Komen is synonymous with efforts to harness education, advocacy, research and global outreach to improve outcomes and race toward a cure for all forms of the disease.


Ingrid Mayer, MD, MSCI

Earlier this summer, Susan G. Komen CEO Paula Schneider visited Middle Tennessee and met with Nashville Medical News to discuss the organization's bold goals and a new initiative to address disparities. Schneider, herself a breast cancer survivor, was joined by Ingrid Mayer, MD, MSCI, leader of the Vanderbilt-Ingram Cancer Center Breast Cancer Research Program and a Komen Scholar.


Addressing Disparities

Schneider said the organization is rolling out a focused program in 11 cities across the country, including Memphis, that have the biggest disparities in breast cancer death rates for African-American women. In fact, she stated, "Memphis has the highest disparate death rate of any city in the country."

With a tag line of 'where you live shouldn't determine whether you live,' the project's goal is to reduce African-American breast cancer death disparities by 25 percent within five years in the pilot cities. "We've been working in disparities in healthcare for years," Schneider said, but noted the new initiative builds on that foundation. "We are working in a collaborative way with thought leadership in each city," she continued of seeking guidance to understand "the story behind the story" in order to launch the most effective interventions and research projects for each community.

The new disparities project, she noted, was made possible by a grant from the Fund II Foundation. As an aside, Schneider explained Fund II is part of the philanthropic works of Robert F. Smith, who made headlines in May when he announced he would pay off student loans for the Morehouse College Class of 2019.

The project builds off of proof-of-concept work done in Chicago and expands that work to 10 additional cities. After conducting a landscape analysis in Chicago, Schneider said they discovered African-American women were getting nearly as many mammograms as their Caucasian counterparts. However, the death rates were completely disparate. Interestingly, she continued, death rates were about the same in the 1980s and '90s. "But when they got to about 2003, it was at 68 percent more that you died if you were African-American rather than white."

A collective impact study looked at the reasons for the divergent death rates. "It was systemic more than anything else," said Schneider. While there were myriad issues, including financial toxicity that made it more difficult for African-American women to access treatment, one of the biggest issues was in how breasts were being positioned during mammograms and how the imaging studies were read. "So, a lot of it had to do with training," Schneider said of the discovery. Because key findings were missed in the early stages of cancer, African-American women tended to be diagnosed later when the disease was more aggressive.

Partnering with hospitals and other organizations to address the systemic failures and enhance training, the Chicago project showcased how outcomes could be impacted by tailored interventions. "We changed the death rate and brought it down 35 percent in five years," Schneider shared.

Now, those lessons will be applied to other cities. In addition to Chicago and Memphis, the African-American Health Equity Initiative is targeting Atlanta, Dallas, Houston, St. Louis, Philadelphia, Washington, Los Angeles, Oakland, Calif., and Norfolk, Va.

Currently, Komen has established roundtables in each of the expansion cities to lead efforts. Schneider said she anticipates the landscape analysis for each of the pilot cities to be completed by year's end.


Bold Goals

For all those diagnosed with breast cancer, Schneider said, "There's a bold goal ... very bold ... and that's to decrease the death rates by 50 percent by 2026." Recognizing the enormity of the task, she added, "If we don't have a North Star, no one will aim for it."

To hit that target, Schneider said there are two sides to the coin. "One is dealing with the cancers that kill," she said. "The second part is disparities in healthcare."

Schneider continued, "There's really nothing that's going to cure cancer but research." However, she noted, even without another medical breakthrough, there is the ability to decrease breast cancer deaths. "You just have to get people to the care that exists today and figure out what the barriers to care are."

The disparities side of the coin is the focus of the new 11-city initiative, and Schneider said the hope is to replicate that work of partnering with thought leaders and organizations in other cities the future. "Ultimately, if we create this business model, and it proves out as (Chicago) proved out, which we anticipate, then we have the ability to be the backbone for a rollout of more cities. It can become scalable," she stated.


Stopping Cancers that Kill

As for the 'cure side' of the coin, Komen supports ... and is supported by ... a robust research effort. Calling the Komen Scientific Advisory Board (SAB) the 'rock stars' of the field, Schneider said the group is led by George W. Sledge, Jr., MD, chief of the Division of Oncology for Stanford University Medical Center, and Nashville's own Jennifer Pietenpol, PhD, director of the Vanderbilt-Ingram Cancer Center (VICC).

In addition to strategic guidance from the SAB members, the organization also relies on the expertise of Komen Scholars, who are leaders in breast cancer research and advocacy. Chosen for their knowledge and contributions to breast cancer research, the select group leads Komen's scientific peer review process and serves as experts for the organization's international network of affiliates. Additionally, the organization helps fund the promising research lines these scientists are investigating.

VICC's Ingrid Mayer, MD, MSCI, was named a Komen Scholar in 2018. "I have a grant to look into a particular type of breast cancer that is very aggressive called triple-negative breast cancer (TNBC). Even though it's very uncommon in the bigger scheme of things - it's about 15 percent of all breast cancers diagnosed in a year - it disproportionately kills a lot of people," said Mayer.

Schneider a 12-year survivor of TNBC noted, "It's the one you don't want to hear you have."

Racing for the Cure

Race for the Cure® events are held throughout the world and are one of the most visible ways Susan G. Komen raises funds for breast health education, outreach, screening, treatment and research. Recently, Komen has rolled out the More than Pink Walk™, which is part of the Race for the Cure series but focuses on walking instead of running.

Nashville and Chattanooga are two of 26 cities debuting the new More than Pink Walk this fall. Susan G. Komen Central Tennessee is hosting the Nashville area event on Saturday, Oct. 26, at Maryland Farms. For more information on the walk and other area resources, visit KomenCentralTennessee.org.

"It's an aggressive tumor with very few options," Mayer concurred. She explained the 'triple-negative' designation means the cancer is negative for the hormones estrogen and progesterone and the protein HER2 that drive most other forms of the disease. The most common type of the cancer, and one that is often seen as women age, is estrogen-dependent breast cancer, which Mayer said makes up about 65 percent of diagnosed cancers annually.

"The second largest group is HER2-positive breast cancer, which is about 30 percent give or take," she continued, noting there is some overlap with estrogen-positive cancers. "This is a cancer that I would argue may be the one we cure first, even with metastatic disease, because there is a driver for that cancer that is this HER2 gene."

Mayer added, "With the ability to use targeted treatment for this cancer, we have tremendously impacted how often people recur." Even though HER2-positive cancer is as aggressive as TNBC, she said the effectiveness of treatment has created a "good problem of not being able to enroll people in metastatic trials because they don't recur ... so that's an awesome problem to have."

A prolific researcher, Mayer has served as principal investigator on more than 80 clinical trials and leads VICC's Breast Cancer Specialized Program of Research Excellence (SPORE) alongside Pietenpol. Currently, she is principal investigator for a large national TNBC clinical trial.

Unlike HER2, the lack of targets makes it particularly difficult to treat TNBC. "Historically, most of these women have been treated with chemotherapy, which works well to a certain extent," Mayer said, but added that recurrence is not uncommon even in those with stage 1 or 2 TNBC.

Komen is supporting her work in profiling triple-negative cancers. Mayer serves as principal investigator on a large National Cancer Institute study (EA1131), which looks to enroll 750 nationwide, to compare different types of chemotherapies for patients at high risk of recurrence for breast cancer. "We are profiling all those tumors and serially collecting blood from all those women to detect what are the possible mutations or possible findings in the tumor DNA," Mayer said. "Can we find something that is actionable?"

While she continues to search for answers to unlock the TNBC mystery, Mayer is also involved in a study testing the drug ifetroban in patients who have completed cancer treatment for one of five types of cancer, including TNBC, and who show no evidence of disease but are at high risk of recurrence. Instead of "watchful waiting" to see if the cancer returns, the hope is to develop therapies that target tumor cell metastasis to move patients into an era of "proactive prevention."

Schneider said exciting new research lines, effective policymaking, education and outreach are all powerful tools in the quest to stop breast cancer. "There's a lot to be said about women in pink with pitchforks," she laughed. "The power of Komen and the power of the brand is everyone understands what our mission is."

The Powerful Story Behind the Organization

After fighting breast cancer for three years, Susan G. Komen succumbed to the disease in 1980 at the age of 36. Before Komen's death, however, Nancy G. Brinker made a promise to her dying sister to do everything in her power to find a way to stop breast cancer. In 1982, the Susan G. Komen® organization launched with $200 and a shoebox filled with the names of potential donors. Today, the global nonprofit has invested nearly $3 billion to fund the fight in more than 60 countries around the globe.

WEB:

Susan G. Komen

Komen Health Equity Project

VICC Breast Cancer SPORE

 
Share:

Related Articles:


Recent Articles

Ascension Saint Thomas Heart First in State, Region, Ascension to Offer Novel Medical Technique

On February 9, Ascension Saint Thomas Hospital West became the first Ascension hospital in the country and the only medical facility in Tennessee to offer intracoronary brachytherapy, a procedure that helps improve chest pain in patients with stents that have re-narrowed (sometimes called "collapsed") and reduces the chance of them narrowing again in the future.

Read More

Functional Seizures Associated with Stroke, Psychiatric Disorders in Electronic Health Records Study

In a large-scale study of electronic health records, Vanderbilt University Medical Center investigators have determined the prevalence of functional seizures and characterized comorbidities associated with them.

Read More

New survey shows minorities, children missing cancer screenings and vaccinations

52% of adults missing lifesaving screenings to prevent cancer are not rescheduling them

Read More

Sarah Cannon Cancer Institute at Swedish Medical Center Sheds New Light on Brain Tumors

Neurosurgery is a complex and intricate process, and it is important to continuously refine and seek innovative techniques to make it safer, gentler and more precise and effective.

Read More

Study Finds Recommended ICU Sedatives Equally Safe, Effective

Sedative medications used in intensive care are associated with increased delirium, which is in turn connected with higher medical costs and greater risk of death and ICU-related dementia.

Read More

Spectrum Solutions Collaborates with UCLA on Saliva-Based Next-Gen Sequencing (NGS) Liquid Biopsy Research for the Early Detection of Lung Cancer

Study to focus on using saliva in the analysis of cell-free circulating tumor DNA (ctDNA) to accurately and non-invasively detect non-small cell lung cancer (NSCLC).

Read More

DRUG COMPANIES URGED TO PROVIDE DISCOUNTS TO 340B COMMUNITY PHARMACIES

Yesterday, counsel for the American Hospital Association and the five other national groups and three individual hospital systems that sued the Department of Health and Human Services (HHS) over its failure to halt drug company actions that undermine the 340B drug pricing program sent letters demanding that the offending drug companies immediately halt their illegal activities.

Read More

Study Shows Drastic Increases in Opioid-Affected Births

The rate of mothers who had an opioid-related diagnosis when delivering their baby increased by 131% from 2010-2017, as the incidence of babies diagnosed with drug withdrawal, known as neonatal abstinence syndrome (NAS), increased by 82% nationally during that same time period.

Read More

Case Management: Enhancing Revenue, Care Transitions and Patient Outcomes throughout the Hospital System

The importance of hospital and health system case management has grown exponentially over the past 10 years and is now getting attention from leaders throughout the healthcare industry.

Read More

TennCare Block Grant Waiver Approved

More than a year after submitting Amendment 42 to the Centers for Medicare and Medicaid Services (CMS) requesting a waiver to increase flexibility in the administration of the state's Medicaid program, Tennessee has received an affirmative nod to move forward.

Read More

Email Print
 
 

 

 


Tags:
Breast Cancer, Breast Cancer Disparities, HER2, Ingrid Mayer, Paula Schneider, Race for the Cure, Susan G. Komen, TNBC, Triple-Negative Breast Cancer, Vanderbilt-Ingram Cancer Center, VICC
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: